Interested in Participating in a Clinical Study?
If you are interested in participating, connect with your cardiovascular specialist.
For the past 15 years, cardiovascular clinicians have been conducting research at Cottage. More than 30 unique clinical trials have brought innovative technology, life-saving devices and expanded medication choice to Cottage patients that wouldn’t otherwise be available. The treatment options from these clinical trials will continue to enhance existing medical services provided to patients by Cottage clinician researchers.
Cardiovascular research at Cottage Health covers a wide array of cardiovascular expertise of our health care providers. Our research extends to investigational clinical trials (phases III-IV), registries, and retrospective studies. We conduct industry-sponsored trials as well as investigator-initiated studies.
The Cottage Health Research Institute (CHRI) is an integral part of Cottage Health. For more than 20 years, CHRI has offered consultation, liaison, and administrative resources to researchers to support the translation of clinical and academic research.
CHRI works closely with investigators to implement protocols at Cottage Health and assists in participant screening, consenting, enrolling, conducting study visits, and collection and entry of data.
Participation in clinical trials allows Cottage Health to offer the best possible range of treatment options and access to cutting-edge treatments for patients in our own community.
Participants Needed for Following Current Cardiovascular Clinical Trials
Study Sponsor: Boston Scientific
Principal Investigator(s): Aragon (PI), Cogert, Shafer, Gidney, Delio
The ASAP-TOO study is a clinical trial for patients with non-valvular atrial fibrillation who deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen in this group of patients
Study Sponsor: Cleveland Clinic
Principal Investigator(s): Aragon (PI), Shafer
The WATCH-TAVR study is a clinical trial for patients who have been diagnosed with atrial fibrillation and aortic stenosis requiring a transcatheter aortic valve replacement (TAVR).
The purpose of the study is to evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device at the same time as the TAVR procedure, compared to anti-coagulant treatment, in preventing stroke and bleeding episodes for these patients.
Study Sponsor: Abbott Medical Devices
Principal Investigator(s): Aragon (PI), Kumar, Thompson, Shenoda
The XIENCE 28 study is a prospective, single arm, multi-center, open label, non-randomized trial to evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents.
GORE GSO 18-01
Study Sponsor: W.L. Gore & Associates, Inc.
Principal Investigator(s): Aragon (PI), Shenoda, Delio
The GORE GSO 18-01 study is a post approval study assessing the safety and effectiveness of the GORE Septal Occluder device as observed in the REDUCE pivotal IDE study, and evaluating the quality of operator education and training and transferability of trial experience to a post-market setting.
The full study title is “GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study”.
Nationally Recognized Research
TCT Conference in San Francisco
Dr. Joseph Aragon and the Cottage Structural Heart team presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
The Transcatheter Cardiovascular Therapeutics conference is one of the world’s largest and most influential educational meetings specializing in interventional cardiovascular medicine.